Abstracts tagged "Inflammation"

Abstract Number: 1262 • ACR Convergence 2021
Fish Oil Supplementation and Pro-inflammatory and Pro-Resolving Lipid Mediators in Patients with and Without Systemic Lupus Erythematosus
May Choi¹, Nancy Cook², Emma Stevens², Natalya Gomelskaya², Gregory Kotler³, JoAnn Manson³, Jessica Lasky-Su², Raju Tatituri², Samia Mora², I-Min Lee³, Charles Serhan² and Karen Costenbader⁴, ¹Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital, Belmont, MA
Background/Purpose: Omega-3 fatty acid-derived “specialized pro-resolving mediators” (SPM) are low-abundance lipid mediators (LM) central to inflammation resolution. In this cross-sectional study, we investigated whether fish…
Abstract Number: 1654 • ACR Convergence 2021
Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL
Azamat Satybaldyev, Galina Gridneva, Anna Misiyuk, Natalia Demidova, Kamalia Kasumova and Evgeny Nasonov, V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia
Background/Purpose: Comparison of frequency of different clinical features of the natural course at the stage of early rheumatoid arthritis (RA) in patients with young and…
Abstract Number: 0020 • ACR Convergence 2021
Citrullination Drives the Expression of Pro-fibrotic Genes in Rheumatoid Arthritis Fibroblast-like Cells
Peter Maloley, Evan Ryan, Nozima Aripova, Michael Duryee, Bryant England, Ted Mikuls and Geoffrey Thiele, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The pathophysiology of rheumatoid arthritis (RA) is hallmarked by joint inflammation, thickening of the pannus, and resultant joint destruction. Within the synovial tissue, citrullinated…
Abstract Number: 0427 • ACR Convergence 2021
Increased Risk of Severe Infections and Mortality in Patients with Newly Diagnosed Anti-neutrophil Cytoplasmic Antibody–associated Vasculitis: A Population-based Study
Kai Zhao¹, Hui Xie², John Esdaile³ and J. Antonio Avina-Zubieta², ¹Simon Fraser University, Coquitlam, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) are a group of multisystem inflammatory diseases of the small blood vessels. Infections are serious complications in AAV…
Abstract Number: 0940 • ACR Convergence 2021
Overactivation of the Kinase IKK2 Causes a Hand Osteoarthritis-Like Phenotype in Mice
Sergio Ramirez-Perez, kyle Jones, Umesh Gangishetti and Pallavi Bhattaram, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Hand osteoarthritis (OA) presents the highest prevalence among rheumatic diseases. Synovitis is a defining feature in hand OA that has been associated with radiographic…
Abstract Number: 1329 • ACR Convergence 2021
Guselkumab (TREMFYA®) Maintains Resolution of Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Results Through 2 Years from a Phase 3 Study
Proton Rahman¹, Iain McInnes², Atul Deodhar³, Georg Schett⁴, Philip Mease⁵, May Shawi⁶, Daniel Cua⁷, Jonathan Sherlock⁸, Alexa Kollmeier⁹, Xie Xu⁷, Yusang Jiang⁷, Shihong Sheng⁷, Christopher Ritchlin¹⁰ and Dennis McGonagle¹¹, ¹Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ²University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany, ⁵Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁶Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸Janssen Research & Development, LLC and University of Oxford, Spring House, PA, ⁹Janssen Research & Development, LLC, La Jolla, CA, ¹⁰Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ¹¹University of Leeds, Leeds, United Kingdom
Background/Purpose: Guselkumab (GUS), a selective inhibitor of IL-23, significantly improved the diverse manifestations of active psoriatic arthritis (PsA), including dactylitis and enthesitis, in the DISCOVER…
Abstract Number: 1670 • ACR Convergence 2021
Increased Prevalence of Gastroesophageal Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Patompong Ungprasert¹, Nipith Charoenngam², Ben Ponvilawan³, Pitchaporn Yingchoncharoen³ and Jerapas Thongpiya⁴, ¹Cleveland Clinic, Cleveland Heights, OH, ²Mount Auburn Hospital, Boston, MA, ³Mahidol University, Bangkok, Thailand, ⁴Mahdiol University, Bangkok, Thailand
Background/Purpose: Recent experimental studies have suggested that systemic inflammatory response could lead to impairment of lower esophageal function, resulting in gastroesophageal reflux disease (GERD). Epidemiologic…
Abstract Number: 0025 • ACR Convergence 2021
The Modulatory Capacity of Galectin-3 on the Programmed Death-1 Signaling Axis in Rheumatoid Arthritis
Kathrine Pedersen¹, Morten Aagaard Nielsen², Malene Hvid¹, Bent Deleuran¹ and Stinne Greisen¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University / Aarhus University Hopital, Aarhus, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the synovium. Despite a variety of treatments, 30-40% of RA patients fail…
Abstract Number: 0458 • ACR Convergence 2021
Single Cell Profiling Reveals a Wnt-mediated Transcriptional Gradient That Drives Inflammation in Rheumatoid Arthritis Synovial Fibroblast Pathology
Alisa Mueller¹, Angela Zou¹, Emily Taylor², Triin Major², David Gardner³, Adam Croft⁴, Roche Fibroblast Network Consortium⁵, Andrew Filer², Christopher Buckley⁶, Kevin Wei¹, Ilya Korsunsky¹, Soumya Raychaudhuri¹ and Michael Brenner⁷, ¹Brigham and Women's Hospital, Boston, MA, ²University of Birmingham, Birmingham, United Kingdom, ³University of Birmingham, College of Medical and Dental Sciences, Birmingham, United Kingdom, ⁴University of Birmingham, Halesowen, United Kingdom, ⁵Roche Innovation Center Basel, Basel, Switzerland, ⁶University of Oxford, Oxford, United Kingdom, ⁷Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: Synovial fibroblasts are key inflammatory aggressors in rheumatoid arthritis (RA) that mediate cartilage and bone destruction, yet therapies directly targeting these cells are lacking.…
Abstract Number: 0943 • ACR Convergence 2021
Metabolomic Profiling of Synovial Tissue of Patients with Osteoarthritis
Jessica Murillo Saich¹, Roxana Coras², Robert Meyer³ and Monica Guma⁴, ¹University of California San Diego, La Jolla, CA, ²University of California San Diego/Department of Medicine, Autonomous University of Barcelona, San Diego, CA, ³San Diego VA Healthcare Service, La Jolla, CA, ⁴University of California San Diego/San Diego VA Healthcare Service/Department of Medicine, Autonomous University of Barcelona, La Jolla, CA
Background/Purpose: Increasing evidence indicates that osteoarthritis (OA) progression is mediated not simply by progressive degeneration of cartilage, but also by low-grade synovial inflammation (synovitis) that…
Abstract Number: 1341 • ACR Convergence 2021
Ixekizumab Shows a Pattern of Pain Improvement in Patients with and Without Measurable Inflammation in Psoriatic Arthritis
Kurt de Vlam¹, Gaia Gallo², Philip Mease³, Proton Rahman⁴, Venkatesh Krishnan², David Sandoval², Chen Yen Lin², Danting Zhu², Rebecca Bolce² and Philip Conaghan⁵, ¹University Hospitals Leuven, Leuven, Belgium, ²Eli Lilly and Company, Indianapolis, IN, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁴Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: The efficacy of ixekizumab (IXE) and adalimumab (ADA) in patients with psoriatic arthritis (PsA) has been previously reported using ACR 50 and Psoriasis Area…
Abstract Number: 1767 • ACR Convergence 2021
CXCL5 Dampens Inflammation in Murine Lupus by Orchestral Suppression of Effector Cell Proliferation and Leukocyte Extravasation
Xiubo Fan¹, Chin Teck Ng¹, Dianyang Guo¹, Frances Lim¹, Annie Law², Julian Thumboo¹, William Hwang³ and Andrea Low¹, ¹Singapore General Hospital, Singapore, Singapore, ²Singhealth, Singapore, Singapore, ³National Cancer Centre Singapore, Singapore, Singapore
Background/Purpose: Systemic lupus erythematosus (SLE) is a potentially fatal autoimmune disease characterized by dysregulation of both innate and adaptive immunity. Current therapeutic options are limited,…
Abstract Number: 0045 • ACR Convergence 2021
Endothelial Cells from Patients with DMARD Naïve, Active Inflammatory Arthritis Demonstrate Pro-inflammatory Sensitisation That Is Reversed by Therapy Initiation
Robert Maughan¹, Marie Lang¹, Anton Olsson¹, Andrew Porter¹, Antonia Greeves², Taryn Youngstein³, Charis Pericleous¹ and Justin Mason¹, ¹Imperial College London, London, United Kingdom, ²Hammersmith Hospital, London, United Kingdom, ³Hammersmith Hospital & Imperial College London, London, United Kingdom
Background/Purpose: Inflammatory arthritides (IA) including rheumatoid arthritis are associated with increased cardiovascular disease (CVD) mortality. Although inflammation-driven endothelial dysfunction is considered a major factor, the…
Abstract Number: 0468 • ACR Convergence 2021
During Development of Rheumatoid Arthritis, Intermetatarsal Bursitis May Occur Before Clinical Joint Swelling: A Large MRI Study in Patients with Clinically Suspect Arthralgia
Bastiaan van Dijk¹, Fenne Wouters¹, Elise van Mulligen², Monique Reijnierse¹ and Annette H.M van der Helm-van Mil¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Inflammation of the synovial lining is a hallmark of rheumatoid arthritis (RA). A synovial lining is not only present at synovial joints and tendon…
Abstract Number: 1000 • ACR Convergence 2021
Molecular Mechanism of Inhibition of CD38 in Attenuation of Monosodium Urate Crystal-induced Inflammatory Responses in Macrophages
Huaping Qin¹, Patricia Oliveira¹, Tiffany Yan¹, Robert Terkeltaub² and Ru Liu Bryan³, ¹University of California San Diego, La Jolla, CA, ²VA/UCSD, San Diego, CA, ³University of California San Diego and VASDHS, San Diego, CA
Background/Purpose: CD38 can function as a degrading enzyme of nicotinamide adenine dinucleotide (NAD), a critical metabolic intermediate serving as enzyme cofactor in redox reactions and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.